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High blood pressure is the leading cause of stroke and a major risk factor for heart
attack and angina pectoris (1). Angiotensin receptor antagonists (ARBs) have been used
extensively for treating high blood pressure. Losartan is the first drug in its class to be
used clinically for the treatment of high blood pressure. The mode of administration has
traditionally been via the oral route. Currently, this drug is administered orally with a
bioavailability of about 30 % and a half-life of 1.5–2.5 hours (2). Its metabolite, (2-n-butyl-
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The potential for nasal delivery of losartan, a drug with
poor oral bioavailability, was investigated using Calu-3
cells. Epithelial permeation of the drug with or without
dimethyl-b-cyclodextrin (DM-b-CD) and glycocholate was
investigated. Possible transport mechanism of the com-
pound and epithelial mucosal tolerance were screened.
Reversibility of epithelial membrane perturbation was also
investigated by measuring transepithelial electrical resis-
tance (TEER) recovery over a 24-h period following drug
formulation exposure. The permeability coefficient of lo-
sartan was 1.3 ± 0.5 ´ 10–6 cm s–1. This flux was not sig-
nificantly different from that of formulations containing
DM-b-CD (0.5 and 1.0 %) or glycocholate (0.5 %). How-
ever, the formulation with 1.0 % glycocholate significantly
increased losartan permeation 7-fold. Losartan flux across
the cells was concentration-dependent. Serosal to muco-
sal permeation was significantly higher than mucosal to
serosal permeation. Concentration-dependency, as well as
polarity in transport indicated that the flux of the com-
pound across Calu-3 cells was not limited to passive dif-
fusion. Cells exposed to DM-b-CD (0.5 and 1.0 %) and
glycocholate (0.5 %) caused no significant change in TEER
and mitochondrial dehydrogenase activity (MDH). The
results of the study showed that losartan may be a suit-
able drug candidate for nasal delivery.
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-4-chloro-1-[(2’-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] imidazole-5-carboxylic acid (EXP
3174) is more potent and may have therapeutic potentials due to its extended half-life of
3–9 hours (3).
To mitigate some of the problems associated with oral delivery of losartan, it is rele-
vant to explore other possible delivery options such as nasal or pulmonary routes. Data
generated from this study will provide some clues on some strategies for improving the
bioavailability of the compound by inhalational routes. When administered nasally,
some drugs have advantages including the by-passing of hepatic first pass metabolism
by the liver, rapid onset of the therapeutic effect, reduced gastrointestinal-related side ef-
fects, and attainment of high bioavailability due to higher molecular mass cut-off of the
nasal epithelium (4, 5). In vitro, ex vivo and in silico models are often used to optimize
drug absorption across various biological epithelia (6). These approaches not only speed
up drug development process but they lead to cost reduction and offer unique mecha-
nistic possibilities in terms of investigating drug absorption mechanisms and enhance-
ment strategies. In order to assess the potential of losartan for nasal administration, an
in vitro cell culture model (Calu-3 cells) was used to screen the absorption characteristics
of the compound across the respiratory epithelium. The aim of this study was to explore
the possibility of nasal delivery of losartan using an in vitro tissue culture model (Calu-3
cells). Although Calu-3 cells are of tracheo-bronchial origin, we decided to use them be-
cause of the similarity between the nasal mucosa and Calu-3 cells and the fact that Calu-
-3 cells have been used to study nasal drug absorption (7, 8). Furthermore, other tra-
cheo-bronchial cells such as EpiAirway® cells have been used to investigate nasal drug
absorption in vitro (9, 10). Although losartan is a tetrazole non-peptide molecule, it ex-
hibits some characteristics of peptides, such as low transepithelial permeability and an-
tagonism of angiotensin-AT1 receptors. Therefore, strategies used to improve peptide
absorption may be employed for this molecule due to its low flux characteristic. The cla-
ssical approach that we adopted was the use of absorption enhancers (glycocholate and
DM-b-CD). Glycocholate and DM-b-CD were selected because of their efficacy and sa-
fety at the concentrations investigated (11).
EXPERIMENTAL
Materials
Losartan, its active metabolite EXP 3174 and internal standard for HPLC (5,7-dime-
thyl-2-ethyl-3-[2’-(1H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl-3H-imidazo[4,5-b]pyri-
dine monohydrate (L-158809) were provided as a gift by Merck Sharp and Dohme, USA.
Ammonium dihydrogen orthophosphate, acetonitrile, methanol, sodium azide, triethy-
lamine and N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) were purcha-
sed from Fisher Scientific (Canada). Glycocholate and DM-b-CD were purchased from
Acros Organics (USA). Tissue culture materials including Dulbecco’s Modified Eagle’s
Medium-Ham’s F-12 nutrient (DMEM/F-12), fetal bovine serum (FBS), phosphate buf-
fered saline (PBS), penicillin/streptomycin, glutamax, and phosphate-buffered saline-tryp-
sin were purchased from Invitrogen (Canada).
396
M. Amoako-Tuffour et al.: Permeation of losartan across human respiratory epithelium: An in vitro study with Calu-3 cells, Acta
Pharm. 59 (2009) 395–405.
Methods
Cell culture conditions for Calu-3 cells. – Calu-3 cells were generously donated by Dr.
Elizabeth Cowley, Department of Physiology Dalhousie University (Halifax, Canada).
The cells were maintained in culture using a standard protocol. The cells were cultured
in a 1:1 DMEM/F-12 nutrient mixture supplemented with 10 % FBS, 100 U mL–1 penicil-
lin, and 100 mg mL–1 streptomycin. Initially, they were grown submerged in the culture
medium for 3 days. After this period, they were maintained at an air-liquid interface by
not including the culture medium in the donor compartment of the inserts. The receiver
compartment contained 1000 mL of 10 % FBS, which was changed every 48 h until the
cells were used for transport experiments (usually within 7–10 days post culture estab-
lishment). All cell batches were grown on Costar® Transwell® clear (Corning Inc., USA),
diameter 12 mm, 0.4 mm pore-size polyester membrane, in the presence of 5 % CO2 and
95 % O2 at 37 °C.
Permeation studies. – Immediately before permeation studies, the cells were washed
twice with transport medium (Hanks’ balanced salt supplemented with HEPES buffer
and glucose, pH 7.4). They were the equilibrated by pre-incubation with this medium
for 30 minutes at 37 °C. Transport studies were initiated by adding 250 mL of losartan to
the donor compartment and 1000 mL of the transport medium to the acceptor chamber.
For concentration-dependency studies, four different losartan concentrations were inve-
stigated (50, 100, 400 and 5000 mmol L–1). At pre-determined time points (0–120 min),
100 mL aliquots were sampled from the receiver compartment (except for studies involv-
ing polarity in transport where samples were taken from the donor compartment). The
removed samples were replaced immediately with an equal volume of transport me-
dium. The cells were checked for epithelial integrity before and after experiments by
measuring transepithelial electrical resistance. The cells were washed with transport me-
dium twice before measuring the resistance. Electrical resistance of the cells was mea-
sured using EVOM®, which was connected to an end EV-Ohm Chamber (World Preci-
sion Instruments, USA). Additionally, the permeation of 1 mg mL–1 sodium fluorescein
was measured after transport studies in order to confirm transepithelial electrical resis-
tance (TEER) studies. This was performed for each batch of experiments. For studies in-
volving reversibility of epithelial perturbation by the formulations, TEER was measured
before formulation exposure and was monitored for 24 h. To do this, the cells were
washed twice after transport studies and were transferred to new culture media. TEER
was subsequently measured at 0, 0.25, 0.5, 0.75, 1, 3 and 24 h time points. During this pe-
riod, the cells were incubated at 37 °C with DMEM/F-12 supplemented with 10 % FBS
in a stable tissue culture environment (95 % O2/5 % CO2).
Apparent permeability coefficient (Papp) for losartan transport was calculated accor-
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⎠⎟ is the linear mass flux to receiver solution, A is the epithelial cell surface
area, c0 is the initial concentration of losartan in formulation, V is the volume of receiver
solution and t is time.
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where AP is apical and BL is basolateral. A ratio greater than 1 (12) indicates involve-
ment of an efflux transporter.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolinium bromide (MTT) assay. – MTT as-
say was used to monitor cell viability following exposure to losartan formulations. At
the end of permeation studies, the inserts with Calu-3 cells were washed 3 times by im-
mersion into a beaker of transport medium. Rinsed inserts were transferred into clean
6-well plates, which were filled with 600 mL of MTT (2 mg mL–1) so that the solution was
in contact with the insert membrane. The cells were then incubated for 3 hours at 37 °C.
At the end of the incubation period, the inserts were removed from the MTT solution,
blotted dry on a paper towel and transferred to 6-well plates containing 3 mL isopropyl
alcohol (Sigma-Aldrich, Canada). An additional 1.0 mL of the alcohol was placed on the
apical surface of the cells. Formazan crystals were extracted for 2 h on a Delfia® plate
shaker (slow-speed module) (Wallac, Germany) with the inserts sealed with parafilm to
prevent evaporation. They were also protected from light with aluminum foil wraps. At
the end of the extraction period, the extracted solution from the apical and basolateral
sides of the cells were collected and mixed. Subsequently, 700 mL of the solution from
each insert was transferred to disposable plastic micro-cuvettes. Formazan absorbance
was measured spectrophotometrically at 570 nm using a Cary 50 Bio UV-Visible Spectro-
photometer (Varian PTY Ltd, Australia). Isopropyl alcohol solution was used as blank
solvent. To improve data quality, absorbance adjustment was made by subtracting the
absorbance obtained at 650 nm from the values at 570 nm.
Losartan formulations used for the transport and toxicity studies were prepared by
dissolving a specific amount of losartan powder in phosphate buffered saline. For stud-
ies with absorption enhancer, the drug was dissolved in PBS containing either 0.5 or 1.0
% (m/V) glycocholate or DM-b-CD.
High performance liquid chromatography (HPLC). – The assay of losartan by HPLC was
based on a previously published method (13) that was validated for this study. The HPLC
system consisted of a 250 ´ 3.0 mm internal diameter C18 reversed phase analytical col-
umn (Gemi®, Phenomenex, USA) with a 4.0 ´ 4.0 mm i.d. C18 5-mm reversed phase car-
tridge guard column (Lincrocart, Merck, Germany), a Shimadzu SPD-20A UV detector
(Shimadzu, USA) set at 254 nm and an HP 3395 Integrator (Agilent Technologies, USA).
The mobile phase comprised 0.01 mol L–1 ammonium dihydrogen orthophosphate bu-
ffer-acetonitrile-methanol (45:30:25) with 0.02 % sodium azide and 0.04 % triethylamine
and final pH adjusted to 3.2. The system was operated isocratically at ambient tempe-
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rature and a flow rate of 0.5 mL min–1. The operating pressure was maintained between
11.7 and 13.7 kPa. Losartan, its active metabolite EXP3174 and the internal standard
(L-158809) were separated without interference from other compounds (e.g., diltiazem,
verapamil, AZT, dipyridamole, nifedipine, cytarabine and propranolol). Precision within
assay (or within day) was lower than 10 %. The standard curves were linear from 0.1 to
1.0 mg mL–1 for losartan and EXP 3174 with an R of 0.9985 and 0.9970, respectively.
Statistical data analysis. – Unless otherwise stated, each in vitro experiment was per-
formed in triplicate using different inserts and the data were expressed as mean ± SD.
Student’s t-test was used to compare the effects of formulation excipients on TEER
change, sodium fluorescein permeation and tissue viability relative to control (cells in-
cubated with transport medium or PBS).
RESULTS AND DISCUSSION
Figs. 1a,b show the data on in vitro permeation of losartan, with and without ab-
sorption enhancers across Calu-3 cells. The permeability coefficient (Papp AP-to-BL) of the
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Losartan alone (control) Glycocholate (0.5 %) Glycocholate (1.0 %)
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Fig. 1. Permeation across Calu-3 cells of losartan formulated with: a) glycocholate and
b) dimethyl-b-cyclodextrin. Points are mean ± SD, n = 3.
compound without any formulation additive was (1.3 ± 0.5) ´ 10–6 cm s–1. Papp AP-to-BL
in formulations containing absorption enhancers was (1.3 ± 0.5) ´ 10–6 (0.5 % DM-b-CD),
(2.2 ± 0.2) ´ 10–6 (1.0 % DM-b-CD), (1.1 ± 0.1) ´ 10–6 (0.5 % glycocholate), and (8.7 ± 1.1) ´
10–6 cm s–1 (1.0 % glycocholate). The enhancement factor for losartan permeation was
0.9–7.2.
The Papp AP-to-BL for losartan without enhancers was not significantly different from
that of the formulations with DM-b-CD (0.5 and 1.0 %) and glycocholate (0.5 %). How-
ever, there was a significant increase (p < 0.05) in the drug absorption with 1.0 % glyco-
cholate. For the formulations investigated, the active metabolite of losartan, EXP3174,
was not detected during transport experiments. This implied that losartan was intact dur-
ing the two-hour permeation period. It is therefore possible that metabolism did not play
a limiting role in the compound permeability under our experimental conditions.
Concentration had a significant effect on the flux of the compound. The apical to
basolateral transport was concentration-dependent (Fig. 2). The concentration-depend-
ent decrease in permeability coefficient of the compound was observed as concentration
increases from 50 to 5000 mmol L–1. This could be due to saturation of peptide transport-
ers responsible for active transport of the compound across the epithelial cells. The per-
meation of losartan across the cells also exhibited polarity in transport.
Results of the bi-directional studies are highlighted in Fig. 3. The losartan perme-
ability coefficient for basolateral-to-apical transport was 8-fold higher than apical-to-ba-
solateral permeation. This possibly implies that the permeation of losartan in Calu-3 cells
was limited by an efflux transport system. Losartan flux in Calu-3 cells was 2.6 to 5.2-fold
higher than the rates reported for Caco-2 and MDCK cell lines (14, 15). Furthermore, the
permeability ratio in favour of basolateral-to-apical transport observed in this study
(8-fold) was approximately half of the permeability ratio reported for the Caco-2 cell cul-
ture system. It is important to emphasize that the permeability coefficient observed for
losartan in various epithelial models is relatively low considering the low molecular mass
of the compound (422.911 g mol–1). Some hypotheses including the possible metabolism
by intestinal CYP3A4, first-pass metabolism by the liver and intestinal counter-transport
by P-glycoprotein efflux transporters may suffice to explain the low and variable bio-
availability of the compound after oral administration. In this study, the low permeation
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Fig. 2. Effect of losartan concentration on perme-
ation across Calu-3 cells. Points are mean ± SD,
n = 3.
of the compound across the respiratory cells in the absence of an enhancer may not be
attributed to its metabolic clearance during transport as EXP371; the major metabolite of
the compound was not detected. Losartan is a substrate of P-glycoprotein efflux pump
(16), which is expressed in Calu-3 cells (17) and Caco-2 culture systems (18). However,
these efflux pumps have not been shown to be expressed in the nasal epithelium. There-
fore, the observed efflux in Calu-3 cells may not limit the bioavailability of the compound
following nasal administration.
Fig. 4 shows the effect of losartan prepared with absorption enhancers on mucosal
tolerance using the decrease in TEER (Fig. 4a) and sodium fluorescein permeation (Fig.
4b) as toxicity indices. The mean TEER value of the cells before permeation studies was
523 ± 86 (n = 12). Following exposure to the losartan formulations, the TEER of the cells
was between 60–88 % of their initial values. Furthermore, the mean permeation of sodium
fluorescein following formulation exposure for 2 h was 0.7 ± 0.0 % (glycocholate 0.5 %),
1.3 ± 0.1 % (glycocholate 1.0 %), 1.0 ± 0.4 % (DM-b-CD 0.5 %), and 1.0 ± 0.3 % (DM-b-CD
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Fig. 3. Effect of polarity on losartan (100 mmol L–1)
permeation across Calu-3 cells. Points are mean































































Fig. 4. Effect of losartan formulation on: a) transepithelial electrical resistance and b) paracellular
marker permeation in Calu-3 cells. Points are mean ± SD, n = 3.
1.0 %). Considering the relatively low sodium fluorescein permeation in one hour, and
the results of TEER reduction, it appears that the formulations may not have any signifi-
cant detrimental effect when used in vivo. To support this hypothesis, it was necessary to
find out whether the observed TEER reduction and sodium fluorescein permeation were
accompanied by significant cytotoxicity. This was investigated by screening the ability
of the cells to convert MTT to formazan crystals (mitochondrial dehydrogenase activity,
MDH) after 2-h incubation with losartan formulation. Viability of the cells after drug ex-
posure is summarized in Fig. 5. Cells incubated with PBS served as a negative control.
The MDH activity after treatment with the transport medium was not significantly dif-
ferent from that of the cells exposed to the test compounds, except for cells treated with
1.0 % glycocholate (p < 0.05). Considering the effect on epithelial viability that was ob-
served for 1.0 % glycocholate, it was important to find out whether the cells could re-
cover from this effect in a timely manner. Since the MTT assay is a terminal method, it
was not suitable to investigate cellular recovery, which is a time dependent effect. As an
alternative, we monitored the change in TEER of the cells exposed to the formulations
for 24 h following drug exposure.
Figs. 6a,b show the change and recovery of TEER in cells exposed to various formu-
lations of losartan. Cells that were exposed to losartan formulations with glycocholate
(Fig. 6a) had a faster recovery rate than cells exposed to DM-b-CD formulations (Fig.
6b). For cells exposed to formulations with glycocholate, no significant recovery was ob-
served up to 1 h after the drug exposure. However, there was significant recovery (p <
0.05) after 3 h, especially for cells exposed to formulations with 0.5 % glycocholate. After
24 h more than 50 % recovery was observed for cells exposed to both 0.5 and 1.0 % glyco-
cholate formulations. As for cells exposed to DM-b-CD, the recovery pattern was quite
different from that of glycocholate. TEER values for the two formulations continued to
decline up to 3 h following drug exposure. A positive change in TEER was observed only
after a 24-h recovery period compared to 3 h observed for glycocholate-containing for-
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Fig. 5. Effect of losartan formulation on viability of
Calu-3 cells after a 2-h incubation period. Points are
mean ± SD, n = 3. PBS – phosphate buffered saline,
DM-b-CD – dimethyl-b-cyclodextrin. * – significantly
different from control, p < 0.05.
mulations. The most important observation was that within the 24-h recovery period,
TEER stopped declining and started to increase. Both the rate of TEER decline and its
rate of recovery were concentration-dependent. In general, the cells exposed to the for-
mulations began to recover from the effects of the formulations within 24 h. Although
some reports have shown that glycocholate and DM-b-CD may cause various degrees of
epithelial damage (19, 20), these effects may be dependent on the concentration and ex-
posure times of the formulations containing enhancers. Although losartan formulated
with 1.0 % glycocholate showed reduced mitochondrial dehydrogenase activity, the ob-
served recovery of TEER within 24 hours following exposure to the formulations implies
the possibility of using both DM-b-CD and glycocholate in preparing losartan formula-
tions for nasal administration. Reversibility is an important aspect of epithelial perturba-
tion by drugs or formulation excipients because it is rare to have any form of drug ab-
sorption enhancement without modification of the tight junction or the epithelial mem-
brane. Therefore, the most relevant issue to consider is the reversibility of epithelial per-
turbation at the concentration range to be employed for absorption enhancement.
CONCLUSIONS
Losartan permeation was significantly increased by glycocholate. It also reversibly
modified transepithelial resistance. Data generated from this study has provided some
insights into the possible absorption enhancement strategies for nasal administration of
losartan. Systemic delivery of this compound via the nasal route could result in higher
CNS bioavailability and reduction of side effects related to dose escalation common in
oral administration.
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Fig. 6. Reversible effect of losartan formulated with: a) glycocholate and dimethyl-b-cyclodextrin
on Calu-3 cells. Cells were exposed to formulations for 2 h and reversibility was assessed over a
24-h period. Points are mean ± SD, n = 3.
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S A @ E T A K
Permeacija losartana kroz humani respiratorni epitel:
In vitro ispitivanja na Calu-3 stanicama
MICHELLE AMOAKO-TUFFOUR, POLLEN K. YEUNG i REMIGIUS U. AGU
U radu je ispitivana mogu}nost nazalne primjene losartana, lijeka sa slabom bioraspo-
lo`ivo{}u nakon peroralne uporabe, koriste}i Calu-3 stanice. Ispitivana je permeacija lije-
ka kroz epitel u prisutnosti dimetil-b-ciklodekstrina (DM-b-CD) i glikokolata te bez nji-
hove prisutnosti. Predlo`en je mogu}i mehanizam transporta kroz epitel i odre|ena je
tolerancija epitelne mukoze. Reverzibilnost promjena u epitelu pra}ena je mjerenjem po-
vrata transepitelnog elektri~nog otpora (TEER) kroz razdoblje od 24 h nakon izlaganju
pripravku lijeka. Koeficijent permeabilnosti losartana bio je 1.3 ± 0.46 ´ 10–6 cm s–1. Taj
se dotok zna~ajno ne razlikuje od pripravaka koji sadr`e DM-b-CD (0,5 i 1,0 %), odno-
sno glikokolat (0,5 %) (faktor pove}anja  1,0). Me|utim, iz pripravka s 1,0 % glikokolata
pove}ala se permeacija losartana 7 puta. Protok losartana kroz stanice ovisio je o kon-
centraciji. Permeacija iz seruma u mukozu bila je zna~ajno ve}a nego u obrnutom smjeru.
Ovisnost o koncentraciji te polarnost u transportu ukazuju na to da protok losartana kroz
Calu-3 stanice nije ograni~en samo na pasivnu difuziju. Stanice izlo`ene dimetil-b-ciklo-
dekstrinu (0,5 i 1,0 %) i glikokolatu (0,5 %) nisu uzrokovale zna~ajne promjene TEER-a i
aktivnosti mitohondrijske dehidrogenaze (MDH). Rezultati pokazuju da je losartan po-
godan za nazalnu isporuku.
Klju~ne rije~i: permeacija, losartan, nazalna apsorpcija, Calu-3 stanice
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